Начало・Списък с акции・Novavax Inc

Novavax Inc

Затворен

СекторЗдравеопазване

7.65 3.1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.4

Максимум

7.6899999999999995

Ключови измерители
By Trading Economics
Приходи	-27M -9.5M
Продажби	-7.6M 140M
P/E Средно за сектора	3.112 64.641
EPS	-0.06
Марж на печалбата	-6.803
Служители	749
EBITDA	-29M -543K

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+45.07% upside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-89M 1.2B
Предишно отваряне	4.55
Предишно затваряне	7.65

Настроения в новините

By Acuity

50%

151 / 340 Класиране в Healthcare

Novavax Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 23:46 ч. UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

31.07.2026 г., 19:16 ч. UTC

Novavax Inc. shares are lower today, reflecting a decline from Thursday's close amid rising bond yields and crude oil prices contributing to inflation concerns.

30.07.2026 г., 22:01 ч. UTC

Novavax Inc. shares advanced in after-market trading, rebounding from earlier session lows, though they remain below the 20-day moving average.

29.07.2026 г., 23:06 ч. UTC

Novavax Inc. shares are higher in after-market trading, gaining slightly since Wednesday's close, despite broader market weakness and significant declines over the past month.

28.07.2026 г., 16:06 ч. UTC

Novavax Inc. shares are lower today, reflecting broader market declines amid investor caution ahead of earnings and the Federal Reserve's interest rate decision.

27.07.2026 г., 14:02 ч. UTC

Novavax Inc shares are higher in pre-market trading, rising to $7.73. This increase occurs amid three consecutive lower session closes and mixed economic data.

24.07.2026 г., 18:46 ч. UTC

Novavax Inc. shares are lower today, continuing a trend of declines following three consecutive sessions of lower closes and trading below the 20-day moving average.

23.07.2026 г., 09:01 ч. UTC

Novavax Inc shares are higher in pre-market trading, reflecting upward momentum since Wednesday. Broader market sentiment remains positive amid rising Asian equity indices.

22.07.2026 г., 23:11 ч. UTC

Novavax Inc. shares are higher in after-market hours, driven by strength in biotechnology stocks. The company remains below its 20-day moving average.

21.07.2026 г., 22:46 ч. UTC

Novavax Inc. shares declined in after-market trading, remaining below their 20-day moving average despite a broader market rebound in the tech sector.

20.07.2026 г., 23:46 ч. UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

Novavax Inc Прогноза

Ценова цел

By TipRanks

45.07% нагоре

12-месечна прогноза

Среден 10.75 USD 45.07%

Висок 19 USD

Нисък 7 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Novavax Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Novavax Inc през последните 3 месеца.

Настроение

By Acuity

151 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.